Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Modus Gets Phase IIa Trial Approval for CKD Therapy in Clinical Advancements
Details : Modus is set to advance the clinical development of its lead product, Sevuparin, for the treatment of chronic kidney disease.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Imperial College London
Deal Size : Undisclosed
Deal Type : Partnership
Modus Therapeutics Partners with Imperial College London on Malaria Drug
Details : Modus is currently developing sevuparin in sepsis/septic shock, and other conditions with systemic inflammation, with severe malaria being a further example. These conditions constitute major healthcare problems.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
November 06, 2021
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Imperial College London
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 25, 2019
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Ergomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 05, 2015
Lead Product(s) : Sevuparin,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Ergomed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2011
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
